More than 440 people recently attended the 40th Annnual UNC Lineberger Scientific Symposium, which featured talks on treatments and ongoing research that target the RAS-RAF-MEK-ERK and other signaling pathways in cancer.
A study led by UNC Lineberger researchers has found that for women who have had a false-positive mammogram result, their likelihood to get screened at recommended intervals depends on the timing of their last screen. Louise Henderson, PhD, will present the findings at the American Association for Cancer Research Annual Meeting in New Orleans, Monday, April 18.
Jenny Ting, Ph.D. and her colleagues report research findings in Cell Host & Microbe that further explain the role of host proteins in viral replication and the innate immune response to HIV infection.
Katherine Reeder-Hayes, MD, MBA, and her colleagues report that women age 66 and older who have HER2-positive breast cancer were less likely than younger women to be treated with trastuzumab (Herceptin), a proven, yet expensive, drug therapy.
Recent work from the laboratory of Liza Makowski, PhD, UNC Lineberger member and assistant professor of nutrition at the UNC Gillings School of Global Public Health, explores two possibilities for breaking the link between obesity and basal-like breast cancer.
UNC Lineberger's annual scientific symposium, “Molecularly Targeted Cancer Therapies from Bench to Bedside,” will be held April 11-12 at The William and Ida Friday Center for Continuing Education. Thanks to event supporters, attendance is free and the cost to for lunch is minimal at $16 per day. Registration is open until 5 p.m. on Wednesday, April 6.